Answers are grounded in this paper and cite their sources.
Blood coagulation factor XII (FXII; Hageman factor) is a serine protease. Its NH2-terminal portion binds to negatively charged surfaces, and its COOH-terminal portion contains the enzymatic active site (1). The human FXII gene is located on the chromosomal band 5q33-qter, and 12 kb of the gene (14 exons and 13 introns) have already been sequenced. FXII is converted by activation to a two-chain serine protease with an NH2-terminal heavy chain (Mr 50 000) and a COOH-terminal light chain (Mr 28 000), and activated FXII has been shown in vitro and in vivo to have a pivotal role in several pathways concerned with tissue defense and repair, including the initiation of the intrinsic pathway of blood coagulation and the conversion of plasminogen to plasmin (2). Hereditary FXII deficiency [with almost no (<1%) FXII coagulant activity (FXIIc) in the homozygous or compound heterozygous state] does not cause a bleeding tendency. However, this deficiency can be detected in vitro because of a prolonged activated partial thromboplastin time (aPTT). Results from previous studies have indicated that FXII is involved in the pathogenesis of thrombophilic diseases and coronary artery disease (CAD): One study (3), but not another (4), indicated that decreased FXIIc is a risk factor for thrombophilia, whereas other studies have reported increased FXIIc in people with CAD (5)(6), suggesting a role of FXIIc in the pathogenesis of atherosclerosis. This hypothesis is supported by findings that human endothelial cells possess receptors for FXII (7) and that FXII is activated by fatty acids in vitro (8) and increases postprandially (9). These effects might explain the particularly high risk for CAD in subjects with a disturbed triglyceride metabolism. Recently, a common polymorphism in the 5′-untranslated region of the FXII gene (46C→T) has been described. This polymorphism is associated with lower FXII antigen concentrations and coagulant activity in plasma, occurs more frequently in Orientals than in Caucasians (10), and has been suggested to influence the activity state of the coagulation pathway (11). The biochemical mechanism is thought to be by lower translation efficiency when the T allele is present (10). Genotyping for this polymorphism has been performed by restriction fragment length polymorphism (RFLP) analysis, a method that is time-consuming and difficult to automate because of the postamplification procedures. Another disadvantage of RFLP is that other mutations close to the mutation of interest may give false-positive or -negative results. A false-positive result by RFLP genotyping, e.g., is obtained in carriers of the (silent) factor V A1692C transversion, which is misinterpreted as factor VLeiden mutation after MnlI digestion (12). Our first aim in this study was to establish a rapid and cost-effective system for FXII genotyping and to examine the effects of the different FXII genotypes on the intrinsic pathway, in particular on FXIIc and aPTT. Our second aim was to examine by a cross-sectional approach whether FXII genotypes differ between a group of 110 subjects with CAD and a group of 193 subjects with thrombophilia. We studied 110 outpatients [mean (SD) age, 62.1 ± 9.4 years] from the University Hospital Magdeburg with CAD, as diagnosed by angiography. Angiography was performed within 1 year of blood sampling. For the effects of FXII genotype in thrombophilia, 193 subjects with a history of deep vein thrombosis with or without pulmonary embolism were recruited from the University Hospital Benjamin Franklin in Berlin. The protocol was in accordance with the current revision of the Helsinki Declaration of 1975, and all subjects gave informed consent. As expected, the thrombophilic subjects were younger than the subjects from the CAD study (mean age, 52.0 ± 15.7 years). In all subjects, genomic DNA was isolated from whole blood collected into dipotassium EDTA with the QIAamp DNA Blood Mini Kit (Qiagen). Citrated blood (0.109 mol/L trisodium citrate) was collected from the CAD patients by clean venipuncture and was separated by centrifugation (3000g for 10 min) within 30 min after collection. Plasma was frozen immediately and stored until analysis at −70 °C. For FXIIc determination, we used a clotting assay with FXII-deficient plasma (Dade Behring) and the STA Instrument (Roche Diagnostics). The aPTT was measured using STA APTT LT reagents. For FXII genotyping, we developed an assay for rapid genotyping that uses rapid-cycle PCR and fluorescence resonance energy transfer with the LightCycler System (Roche Molecular Biochemicals) (13)(14). In this assay, a 326-bp fragment harboring exon 1 of the FXII gene was amplified from human genomic DNA with probes matched to published sequence information (10). The inflection point of the peaks of the negative derivative of the fluorescence with respect to temperature vs temperature (−ΔF/ΔT vs T) was used as a surrogate marker for the sequence-specific melting point (Tm). Sequence information for the probes and cycling conditions are available as a supplement from the Clinical Chemistry Web Site. The file can be accessed by a link from the on-line Table of Contents (http://www.clinchem.org/content/vol47/issue6/). When we examined DNA homozygous for the mutated sequence (46T allele), the empirical Tm as obtained by inflection point analysis was 62.06 °C (SD, 0.33 °C; n = 40 alleles), whereas DNA coding for the wild-type allele (46C) produced a Tm of 70.40 °C (SD, 0.42 °C; n = 40 alleles). Heterozygous samples contained both types of targets and thus generated both peaks. Calculated Tm values of 64.3 and 71.3 °C, respectively, were obtained for these probes-target hybrids when the thermodynamic nearest-neighbor model was used (15). The homogeneous system for genotyping allowed easy and unambiguous assignment of genotypes to the respective melting curves. We did not observe melting curve peaks at other temperatures (16). The fluorescence resonance energy transfer technique, however, can be suited to detect many of these mutations, if present (16), in a more selected study group, e.g., in a large group of subjects with FXII 46C homozygosity and very low FXIIc. Distribution of FXII genotypes in 110 subjects of the CAD study and in 186 subjects of the thrombophilia study.1 Allele frequencies were nearly identical among the CAD study and the thrombophilia study groups (frequency of the C allele, 0.765 in the CAD study and 0.785 in the thrombophilia study; P = 0.598). Distribution of FXII genotypes in 110 subjects of the CAD study and in 186 subjects of the thrombophilia study.1 Allele frequencies were nearly identical among the CAD study and the thrombophilia study groups (frequency of the C allele, 0.765 in the CAD study and 0.785 in the thrombophilia study; P = 0.598). In a first application of this procedure, we studied the effects of these polymorphisms in the noncoding region of the FXII gene on FXIIc and aPTT as well as on the correlation of FXIIc and aPTT. We observed a profound effect of FXII genotype on FXIIc (Fig. 1 ): The 46T allele was associated with significantly lower FXIIc than the 46C allele (P <0.05, ANOVA). In addition,. FXIIc and aPTT were negatively correlated [Pearson correlation coefficient (r) of −0.299; P = 0.02; n = 110]. The effect of FXII genotype on aPTT was not significant (P = 0.392). Correlation of FXIIc with aPTT. An inverse correlation of FXIIc with aPTT (P = 0.02; r = −0.299) was observed. The dashed lines indicate the 95% confidence interval. Note the effect of the FXII genotypes on FXIIc. Specifically, the FXIIc difference between 46C/46C (mean FXIIc, 111.6%) and 46C/46T was 28.7% (95% confidence interval, 19.6–37.8%), the difference between 46C/46C and 46T/46T was 54.0% (95% confidence interval, 38.3–69.7%), and the difference between 46C/46T and 46T/46T was 25.3% (95% confidence interval, 8.8–41.8%). We next examined whether the distribution of both FXII alleles differs between subjects with CAD or with thrombophilia. The genotype distribution was in Hardy-Weinberg equilibrium. The allele frequencies of the subjects from the CAD study were compared with the allele frequencies of the subjects from the thrombophilia study. No significant differences were observed (P = 0.598). Gender had no effect on genotype distribution (Table 1 ). When we compared the combined allele frequencies of our study (allele frequency of the T allele, 0.222; total of 606 alleles) with the allele frequencies of an English study (allele frequencies of the T allele, 0.390; total of 902 alleles) (17), a lower frequency of the T allele in our middle-European Caucasian population was noticed. However, a recent very large study (Second Northwick Heart Study) revealed allele frequencies that were not different from the frequencies observed in our study (allele frequency of the T allele, 0.25; total of 5248 alleles; P = 0.141, χ2 test) (11). When the results of the studies discussed above are taken together, the role of FXII genotype as a diagnostic or prognostic marker in CAD or thrombophilia is not yet resolved. Although activated FXII has been shown to be an independent risk factor for CAD and although FXII genotype determines FXIIc and activated FXII by mass action (6)(11), an effect of FXII genotype on CAD has not been demonstrated (11). We postulate that confounders, e.g., specific lipoproteins (9), as well as interference from the preanalytical phase of activated FXII analysis obscure strong effects of the genotype on FXIIc or on activated FXII—a situation that resembles the situation of the methylenetetrahydrofolate reductase genotype and homocysteine concentration (18). In conclusion, we developed an easy-to-perform assay for FXII genotyping and confirmed in a Caucasian population the pronounced effect of the 46C→T polymorphism on FXIIc. In our study of 296 subjects, we did not detect additional mutations in the vicinity of the 46C→T polymorphism of the FXII gene by the hybridization technique used. Our data do not support the hypothesis that FXII genotyping is useful in CAD or in thrombophilic diseases. We are grateful to Birgit Gimpel for excellent technical assistance and to Dr. Nicolas von Ahsen (University of Göttingen) for the Meltcalc Program. M.O. was supported in part by the VeRum Foundation.
No takes yet. Share an insight, caveat, or question.
Orth et al. (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: